Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Short-term Investments (2017 - 2026)

Organogenesis Holdings has reported Short-term Investments over the past 9 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 318.1% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 318.1%, while the annual FY2025 figure was $2.4 million, 318.1% up from the prior year.
  • Short-term Investments for Q4 2025 was $2.4 million at Organogenesis Holdings, up from $627000.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $7.0 million in Q1 2025 and troughed at $487000.0 in Q3 2021.
  • A 5-year average of $1.0 million and a median of $602000.0 in 2021 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: crashed 38.67% in 2023 and later surged 876.81% in 2025.
  • Year by year, Short-term Investments stood at $599000.0 in 2021, then surged by 35.56% to $812000.0 in 2022, then crashed by 38.67% to $498000.0 in 2023, then increased by 16.47% to $580000.0 in 2024, then skyrocketed by 318.1% to $2.4 million in 2025.
  • Business Quant data shows Short-term Investments for ORGO at $2.4 million in Q4 2025, $627000.0 in Q3 2025, and $659000.0 in Q2 2025.